Novavax Inc. (NVAX)
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
Vaccine maker Novavax's shares plunged over 22% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CBS News.
2 Beaten-Down Stocks That Still Aren't Worth Buying
President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day.
FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day.
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $7.91, denoting a -0.57% change from the preceding trading day.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.
Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX ) Leerink Partners 2025 Global Healthcare Conference March 11, 2025 12:00 AM ET Company Participants John Jacobs - CEO Ruxandra Draghia - Head of R&D Jim Kelly - CFO Conference Call Participants Dave Risinger - SVB Leerink Dave Risinger All righty, well thank you everybody for joining and for those of you who don't know me, my name is Dave Risinger and I'm very much pleased to welcome a number of members of the Novavax senior leadership team to be with us here today. Thank you for making the trip to Miami.
Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX ) TD Cowen 45th Annual Health Care Conference March 4, 2025 9:10 AM ET Company Participants John Jacobs - President and Chief Executive Officer Ruxandra Draghia - Executive Vice President & Head of Research & Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Chris LoBianco - TD Cowen Chris LoBianco Great. So I think we'll get started.
